The effect of methotrexate on blood, liver, and renal parameters in patients with rheumatoid arthritis

Background: Rheumatoid arthritis (RA) is a long-term autoimmune disorder that primarily affects joints. The disease may also affect other parts of the body, including the skin, eyes, lungs, heart, nerves, and blood. This study aimed to evaluate the effect of methotrexate on blood, liver, and renal p...

Full description

Saved in:
Bibliographic Details
Main Authors: Bizav Rasheed, Beri Tawfeq
Format: Article
Language:English
Published: Golestan University of Medical Sciences 2024-11-01
Series:Medical Laboratory Journal
Subjects:
Online Access:http://mlj.goums.ac.ir/article-1-1848-en.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850139590335135744
author Bizav Rasheed
Beri Tawfeq
author_facet Bizav Rasheed
Beri Tawfeq
author_sort Bizav Rasheed
collection DOAJ
description Background: Rheumatoid arthritis (RA) is a long-term autoimmune disorder that primarily affects joints. The disease may also affect other parts of the body, including the skin, eyes, lungs, heart, nerves, and blood. This study aimed to evaluate the effect of methotrexate on blood, liver, and renal parameters in patients with RA. Methods: A six-month cross-sectional study was carried out on 60 consecutive patients aged 19-70 years diagnosed with RA on methotrexate treatment (10 mg) orally per week. A questionnaire was taken from participants, and laboratory tests were done on renal and liver function and complete blood count (CBC), erythrocyte sedimentation rate (ESR), glutamic oxaloacetic transaminase (SGOT or AST), glutamate pyruvate transaminase (SGPT or ALT), Creatinine, C-reactive protein (CRP), and rheumatoid factor (RF) as a follow-up to drug intake. Results: At the end of sample collection, participants ranged in age from 19 to 70 years, with a female-to-male ratio of 1.5:1. Significant differences in platelet (PLT) levels were observed only between days 1 and 14 of the treatment (p <0.05). Similarly, SGPT levels showed significant variation between days 1 and 30 of the treatment (p <0.05). Additionally, RF levels exhibited significant differences between days 1 and 14 (p <0.01) and between days 1 and 30 of the treatment (p <0.04). Conclusion: The recommended medication for all kinds of patients with RA is methotrexate, which has had a notable impact on blood, liver, and kidney parameters. These characteristics can serve as indicators for monitoring the medication’s effectiveness, safety, and patient follow-up.
format Article
id doaj-art-dacb022239374b29972c4536b2ca0449
institution OA Journals
issn 2538-4449
language English
publishDate 2024-11-01
publisher Golestan University of Medical Sciences
record_format Article
series Medical Laboratory Journal
spelling doaj-art-dacb022239374b29972c4536b2ca04492025-08-20T02:30:13ZengGolestan University of Medical SciencesMedical Laboratory Journal2538-44492024-11-0118658The effect of methotrexate on blood, liver, and renal parameters in patients with rheumatoid arthritisBizav Rasheed0Beri Tawfeq1 Department of Nursing, College of Health and Medical Techniques-Shekhan, Duhok Polytechnic University, Duhok, Iraq Medical Laboratory Sciences, College of Health Sciences, Duhok University, Iraq Background: Rheumatoid arthritis (RA) is a long-term autoimmune disorder that primarily affects joints. The disease may also affect other parts of the body, including the skin, eyes, lungs, heart, nerves, and blood. This study aimed to evaluate the effect of methotrexate on blood, liver, and renal parameters in patients with RA. Methods: A six-month cross-sectional study was carried out on 60 consecutive patients aged 19-70 years diagnosed with RA on methotrexate treatment (10 mg) orally per week. A questionnaire was taken from participants, and laboratory tests were done on renal and liver function and complete blood count (CBC), erythrocyte sedimentation rate (ESR), glutamic oxaloacetic transaminase (SGOT or AST), glutamate pyruvate transaminase (SGPT or ALT), Creatinine, C-reactive protein (CRP), and rheumatoid factor (RF) as a follow-up to drug intake. Results: At the end of sample collection, participants ranged in age from 19 to 70 years, with a female-to-male ratio of 1.5:1. Significant differences in platelet (PLT) levels were observed only between days 1 and 14 of the treatment (p <0.05). Similarly, SGPT levels showed significant variation between days 1 and 30 of the treatment (p <0.05). Additionally, RF levels exhibited significant differences between days 1 and 14 (p <0.01) and between days 1 and 30 of the treatment (p <0.04). Conclusion: The recommended medication for all kinds of patients with RA is methotrexate, which has had a notable impact on blood, liver, and kidney parameters. These characteristics can serve as indicators for monitoring the medication’s effectiveness, safety, and patient follow-up.http://mlj.goums.ac.ir/article-1-1848-en.pdfc-reactive proteinaspartate aminotransferasesalanine transaminasehemoglobinsmethotrexaterheumatoid factor
spellingShingle Bizav Rasheed
Beri Tawfeq
The effect of methotrexate on blood, liver, and renal parameters in patients with rheumatoid arthritis
Medical Laboratory Journal
c-reactive protein
aspartate aminotransferases
alanine transaminase
hemoglobins
methotrexate
rheumatoid factor
title The effect of methotrexate on blood, liver, and renal parameters in patients with rheumatoid arthritis
title_full The effect of methotrexate on blood, liver, and renal parameters in patients with rheumatoid arthritis
title_fullStr The effect of methotrexate on blood, liver, and renal parameters in patients with rheumatoid arthritis
title_full_unstemmed The effect of methotrexate on blood, liver, and renal parameters in patients with rheumatoid arthritis
title_short The effect of methotrexate on blood, liver, and renal parameters in patients with rheumatoid arthritis
title_sort effect of methotrexate on blood liver and renal parameters in patients with rheumatoid arthritis
topic c-reactive protein
aspartate aminotransferases
alanine transaminase
hemoglobins
methotrexate
rheumatoid factor
url http://mlj.goums.ac.ir/article-1-1848-en.pdf
work_keys_str_mv AT bizavrasheed theeffectofmethotrexateonbloodliverandrenalparametersinpatientswithrheumatoidarthritis
AT beritawfeq theeffectofmethotrexateonbloodliverandrenalparametersinpatientswithrheumatoidarthritis
AT bizavrasheed effectofmethotrexateonbloodliverandrenalparametersinpatientswithrheumatoidarthritis
AT beritawfeq effectofmethotrexateonbloodliverandrenalparametersinpatientswithrheumatoidarthritis